drugset / Trial / NCT03422874
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, dose escalation, phase I study of the combination of MLN9708 plus Nelfinavir.
Timeline
- Start
- 2016-08
- Primary completion
- 2017-08-04
- Completion
- 2017-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 3 mg | Oral |
| Subject | Nelfinavir | Other / unclassified | 1250 mg | Oral |
| Subject | Nelfinavir | Other / unclassified | 1875 mg | Oral |
| Subject | Nelfinavir | Other / unclassified | 2500 mg | Oral |
| Subject | Nelfinavir | Other / unclassified | 3125 mg | Oral |